Issue: 2022, Vol. 27, No. 4
THE PECULIARITIES OF GENETIC AND COAGULATION ALTERATIONS IN WOMEN WITH THREAT OF TERMINATION OF PREGNANCY AND HABITUAL MISCARRIAGE IN THE ANAMNESIS
- Keywords
- habitual miscarriage, thrombophilia, polymorphism of genes, hemostasis
- Abstarct
- Objective – to study the frequency of occurrence of polymorthic genes of hemostasis system in women with habitual miscarriage (HM) in the anamnesis and to compare it with the state of hemostasis in these patients in various terms of pregnancy. Material and methods. The frequency of occurrence of allelic variants of genes of hemostasis system in women with threat of termination of pregnancy before 22 weeks and HM in the anamnesis was analyzed. The determination of gene polymorphism of hemostasis system was carried out by polymerase chain reaction method (PCR) in real time and by reagent kit (city of Novosibirsk) by iCycleriQS (Bio-Rad) device. Hemostasis system evaluation was performed according to the coagulogram. The determination of homocysteine level by immunohemiluminescent method by Immulite 1000 automatic analyzer (Siemens) was made. Results and discussion. The study demonstrated the increase of the frequency of occurrence of polymorphic variants of genes SerpinC1 (-786)A, PROC (-2583)T, PAI-1 (-675)4G, MTRR (-66)G in women with threat of termination of pregnancy and HM in the anamnesis in comparison with women from control group. Statistically significant increase of homocysteine level was revealed in women with threat of termination of pregnancy and HM in the anamnesis in comparison with control group: in the second trimester accordingly 7,1 ± 1,7 mkmole/l, in the control group – 2,6 ± 1,3 mkmole/l (р < 0,05). Conclusion. The obtained results testified to the increase of the frequency of occurrence of polymorphic variants of genes SerpinC1 (-786)A, PROC (-2583)T, PAI-1 (-675)4G, MTRR(-66) in patients with threat of termination of pregnancy and HM in the anamnesis in the absence of statistically significant shifts in clinical coagulogram and clinical thrombosis during present pregnancy.
Vestnik_4_2022-33-38